| 摘要 |
Inhibition of tumour angiogenesis is a promising approach towards restricting tumour growth. Current anti-angiogenic approaches target Vascular Endothelial Growth Factor (VEGF), by either trapping the ligand (anti-VEGF antibody or recombinant protein VEGF-trap) or inhibiting downstream signaling using small tyrosine kinase inhibitors. However, two major problems exist with this approach. First, VEGF has an important role for the proper function of various organs such as the kidney and thyroid, as well as physiological processes such as wound healing. Thus, due to the systemic inhibition of VEGF, a number of side effects have been observed. The second major problem is the aggressive relapse of tumour growth that can be observed over time. To overcome these problems, we engineered the existing VEGF-trap and made it tumour specific, developing a set of 2nd generation VEGF-traps.We also showed that localized systemic expression of VEGF is an effective anti-tumour therapy.
|
